

Elisabetta Antonelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6929536/publications.pdf>

Version: 2024-02-01

55
papers

4,017
citations

159585

30
h-index

175258

52
g-index

56
all docs

56
docs citations

56
times ranked

4884
citing authors

#	ARTICLE	IF	CITATIONS
1	Dermatological Manifestations in Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2021, 10, 364.	2.4	42
2	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.9	36
3	Inhibitors of the Janus Kinases. Journal of Clinical Gastroenterology, 2019, 53, 635-640.	2.2	5
4	Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease. Annals of Diagnostic Pathology, 2019, 38, 20-25.	1.3	7
5	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. Digestive and Liver Disease, 2018, 50, 734-736.	0.9	3
6	Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy. Techniques in Coloproctology, 2018, 22, 941-946.	1.8	13
7	Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World Journal of Gastroenterology, 2018, 24, 5322-5330.	3.3	28
8	Eosinophilia “ associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. Apmis, 2017, 125, 179-183.	2.0	12
9	Enteric glial cells are susceptible to Clostridium difficile toxin B. Cellular and Molecular Life Sciences, 2017, 74, 1527-1551.	5.4	37
10	Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study. Scientific Reports, 2017, 7, 6839.	3.3	19
11	Assessing mucosal healing in ulcerative colitis: the simpler, the better”. Endoscopy, 2015, 47, 759-759.	1.8	4
12	Is It Possible to Identify Patients With Inflammatory Bowel Disease Who Are at Risk for Cytomegalovirus Infection?. Clinical Gastroenterology and Hepatology, 2015, 13, 138-139.	4.4	0
13	The importance of histologic parameters of lacteal involvement in cases of canine lymphoplasmacytic enteritis. Gastroenterology and Hepatology From Bed To Bench, 2015, 8, 33-41.	0.6	8
14	Gastrointestinal motility disorders in inflammatory bowel diseases. World Journal of Gastroenterology, 2014, 20, 37.	3.3	72
15	Colonic motility in ulcerative colitis. United European Gastroenterology Journal, 2014, 2, 457-462.	3.8	34
16	Endoscopic biopsy samples of naïve “œcolitides”-patients: Role of basal plasmacytosis. Journal of Crohn's and Colitis, 2014, 8, 1438-1443.	1.3	28
17	The role of colonic mast cells and myenteric plexitis in patients with diverticular disease. International Journal of Colorectal Disease, 2013, 28, 267-272.	2.2	19
18	Definition and evaluation of mucosal healing in clinical practice. Digestive and Liver Disease, 2013, 45, 969-977.	0.9	107

#	ARTICLE	IF	CITATIONS
19	Pseudomembranous collagenous colitis with superimposed drug damage. Pathology Research and Practice, 2013, 209, 735-739.	2.3	15
20	Prevalence and causes of abnormal liver function in patients with coeliac disease. Liver International, 2013, 33, 1128-1131.	3.9	20
21	Histological healing in inflammatory bowel disease: A still unfulfilled promise. World Journal of Gastroenterology, 2013, 19, 968.	3.3	87
22	Papillary thyroid cancer and ulcerative colitis. Gastroenterology and Hepatology From Bed To Bench, 2013, 6, 52-4.	0.6	5
23	Increase of Colonic Mast Cells in Obstructed Defecation and Their Relationship with Enteric Glia. Digestive Diseases and Sciences, 2012, 57, 65-71.	2.3	24
24	Intestinal superinfections in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis, 2012, 6, 154-159.	1.3	48
25	Ultrasonographic assessment of colonic wall in moderate to severe ulcerative colitis: Comparison with endoscopic findings. Digestive and Liver Disease, 2011, 43, 703-706.	0.9	39
26	Non-IBD colitides: clinically useful histopathological clues. Revista Espanola De Enfermedades Digestivas, 2011, 103, 366-372.	0.3	15
27	Gastrointestinal Foxp3 expression in normal, inflammatory and neoplastic conditions. Pathology, 2011, 43, 465-471.	0.6	3
28	Successful twin pregnancy in a patient with ulcerative colitis using azathioprine during conception. Gastroenterology and Hepatology From Bed To Bench, 2011, 4, 224-7.	0.6	0
29	Inflammatory bowel disease in the dog: Differences and similarities with humans. World Journal of Gastroenterology, 2010, 16, 1050.	3.3	102
30	Pulmonary diseases associated with inflammatory bowel diseases. Journal of Crohn's and Colitis, 2010, 4, 384-389.	1.3	37
31	Enteric neuroglial apoptosis in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2009, 3, 264-270.	1.3	34
32	A Simplified Method for Anal Ultrasonography. Journal of Clinical Gastroenterology, 2009, 43, 453-456.	2.2	1
33	The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2008, 2, 327-330.	1.3	18
34	Enteric glial cells: new players in gastrointestinal motility?. Laboratory Investigation, 2007, 87, 628-632.	3.7	95
35	Enteric glial cells and their role in gastrointestinal motor abnormalities: Introducing the neuro-gliopathies. World Journal of Gastroenterology, 2007, 13, 4035.	3.3	63
36	Evidence That Hydrogen Sulfide Exerts Antinociceptive Effects in the Gastrointestinal Tract by Activating KATP Channels. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 325-335.	2.5	238

#	ARTICLE	IF	CITATIONS
37	Cross-Talk between Farnesoid-X-Receptor (FXR) and Peroxisome Proliferator-Activated Receptor β Contributes to the Antifibrotic Activity of FXR Ligands in Rodent Models of Liver Cirrhosis. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 58-68.	2.5	169
38	The third gas: H ₂ S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. Hepatology, 2005, 42, 539-548.	7.3	504
39	Dual COX-Inhibitors: The Answer is NO?. Current Topics in Medicinal Chemistry, 2005, 5, 487-492.	2.1	8
40	A Farnesoid X Receptor-Small Heterodimer Partner Regulatory Cascade Modulates Tissue Metalloproteinase Inhibitor-1 and Matrix Metalloprotease Expression in Hepatic Stellate Cells and Promotes Resolution of Liver Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 584-595.	2.5	176
41	The Methyl Transferase PRMT1 Functions as Co-Activator of Farnesoid X Receptor (FXR)/9-cis Retinoid X Receptor and Regulates Transcription of FXR Responsive Genes. Molecular Pharmacology, 2005, 68, 551-558.	2.3	74
42	Inhibition of Hydrogen Sulfide Generation Contributes to Gastric Injury Caused by Anti-Inflammatory Nonsteroidal Drugs. Gastroenterology, 2005, 129, 1210-1224.	1.3	367
43	Protective Effects of 6-Ethyl Chenodeoxycholic Acid, a Farnesoid X Receptor Ligand, in Estrogen-Induced Cholestasis. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 604-612.	2.5	190
44	PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology, 2004, 39, 365-375.	7.3	149
45	The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology, 2004, 127, 1497-1512.	1.3	406
46	Treatment of Portal Hypertension with NCX-1000, a Liver-Specific NO donor. A Review of Its Current Status. Cardiovascular Drug Reviews, 2004, 22, 135-146.	4.1	21
47	NCX-1000: a liver-specific NO donor. , 2004, , 105-110.		0
48	The FXR-agonist, 6-ethyl-chenodeoxycholic acid (6-ECDCA), protects against estrogen-induced cholestasis in rats. Gastroenterology, 2003, 124, A698.	1.3	1
49	NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. Journal of Hepatology, 2003, 39, 932-939.	3.7	77
50	Nonlinear partial differential equations and applications: NCX-1015, a nitric-oxide derivative of prednisolone, enhances regulatory T cells in the lamina propria and protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15770-15775.	7.1	72
51	A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway – THIS ARTICLE HAS BEEN RETRACTED. British Journal of Pharmacology, 2002, 135, 589-599.	5.4	31
52	Nitric Oxide-Releasing NSAIDs. Drug Safety, 2001, 24, 801-811.	3.2	74
53	NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 8897-8902.	7.1	128
54	NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology, 2000, 118, 404-421.	1.3	104

#	ARTICLE	IF	CITATIONS
55	Gastrointestinal safety of nitric oxideâ€‘derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology, 1999, 116, 1089-1106.	1.3	148